NMR measurement of LDL particle number using the Vantera® Clinical Analyzer

Clinical Biochemistry

Volumn 47, Issue 16-17, 2014, Pages 203-210

  Matyus, Steven P ^a   Braun, Paul J ^a   Wolak Dinsmore, Justyna ^a   Jeyarajah, Elias J ^a   Shalaurova, Irina ^a   Xu, Yuan ^a   Warner, Suzette M ^a   Clement, Thomas S ^a   Connelly, Margery A ^a   Fischer, Timothy J ^a  

^a LIPOSCIENCE INC   (United States)

Author keywords

Cardiovascular disease; CV risk management; Lipoprotein particle analysis; Low density lipoprotein; NMR spectroscopy

Indexed keywords

LOW DENSITY LIPOPROTEIN CHOLESTEROL;

BLOOD; HUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PROCEDURES; REPRODUCIBILITY;

CHOLESTEROL, LDL; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; REPRODUCIBILITY OF RESULTS;

EID: 84908669603     PISSN: 00099120     EISSN: 18732933     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2014.07.015     Document Type: Article

References (40)

1. Tabas I., Williams K.J., Boren J. Subendothelial lipoprotein retention as the initiating process in atherosclerosis: update and therapeutic implications. Circulation 2007, 116:1832-1844.
2. Assmann G., Nofer J.R. Atheroprotective effects of high-density lipoproteins. Annu Rev Med 2003, 54:321-341.
3. Otvos J.D., Jeyarajah E.J., Cromwell W.C. Measurement issues related to lipoprotein heterogeneity. Am J Cardiol 2002, 90:22i-29i.
4. Cromwell W.C., Otvos J.D. Heterogeneity of low-density lipoprotein particle number in patients with type 2 diabetes mellitus and low-density lipoprotein cholesterol <100mg/dl. Am J Cardiol 2006, 98:1599-1602.
5. Cromwell W.C., Otvos J.D., Keyes M.J., Pencina M.J., Sullivan L., Vasan R.S., et al. LDL particle number and risk of future cardiovascular disease in the Framingham Offspring Study - implications for LDL management. J Clin Lipidol 2007, 1:583-592.
6. Otvos J.D., Mora S., Shalaurova I., Greenland P., Mackey R.H., Goff D.C. Clinical implications of discordance between low-density lipoprotein cholesterol and particle number. J Clin Lipidol 2011, 5:105-113.
7. Malave H., Castro M., Burkle J., Voros S., Dayspring T., Honigberg R., et al. Evaluation of low-density lipoprotein particle number distribution in patients with type 2 diabetes mellitus with low-density lipoprotein cholesterol <50mg/dl and non-high-density lipoprotein cholesterol <80mg/dl. Am J Cardiol 2012, 110:662-665.
8. Degoma E.M., Davis M.D., Dunbar R.L., Mohler E.R., Greenland P., French B. Discordance between non-HDL-cholesterol and LDL-particle measurements: results from the Multi-Ethnic Study of Atherosclerosis. Atherosclerosis 2013, 229:517-523.
9. Rosenson R.S., Underberg J.A. Systematic review: evaluating the effect of lipid-lowering therapy on lipoprotein and lipid values. Cardiovasc Drugs Ther 2013, 27:465-479.
10. Rosenson R.S., Davidson M.H., Pourfarzib R. Underappreciated opportunities for low-density lipoprotein management in patients with cardiometabolic residual risk. Atherosclerosis 2010, 213:1-7.
11. El Harchaoui K., van der Steeg W.A., Stroes E.S., Kuivenhoven J.A., Otvos J.D., Wareham N.J., et al. Value of low-density lipoprotein particle number and size as predictors of coronary artery disease in apparently healthy men and women: the Epic-Norfolk prospective population study. J Am Coll Cardiol 2007, 49:547-553.
12. Otvos J.D., Collins D., Freedman D.S., Shalaurova I., Schaefer E.J., McNamara J.R., et al. Low-density lipoprotein and high-density lipoprotein particle subclasses predict coronary events and are favorably changed by gemfibrozil therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial. Circulation 2006, 113:1556-1563.
13. Mora S., Otvos J.D., Rifai N., Rosenson R.S., Buring J.E., Ridker P.M. Lipoprotein particle profiles by nuclear magnetic resonance compared with standard lipids and apolipoproteins in predicting incident cardiovascular disease in women. Circulation 2009, 119:931-939.
14. Mora S., Szklo M., Otvos J.D., Greenland P., Psaty B.M., Goff D.C., et al. LDL particle subclasses, LDL particle size, and carotid atherosclerosis in the Multi-Ethnic Study of Atherosclerosis (MESA). Atherosclerosis 2007, 192:211-217.
15. Rosenson R.S., Otvos J.D., Freedman D.S. Relations of lipoprotein subclass levels and low-density lipoprotein size to progression of coronary artery disease in the pravastatin limitation of atherosclerosis in the coronary arteries (PLAC-I) trial. Am J Cardiol 2002, 90:89-94.
16. Brunzell J.D., Davidson M., Furberg C.D., Goldberg R.B., Howard B.V., Stein J.H., et al. Lipoprotein management in patients with cardiometabolic risk: consensus statement from the American Diabetes Association and the American College of Cardiology foundation. Diabetes Care 2008, 31:811-822.
17. Arsenault B.J., Despres J.P., Stroes E.S., Wareham N.J., Kastelein J.J., Khaw K.T., et al. Lipid assessment, metabolic syndrome and coronary heart disease risk. Eur J Clin Invest 2010, 40:1081-1093.
18. Mora S., Buring J.E., Ridker P.M. Discordance of low-density lipoprotein (LDL) cholesterol with alternative LDL-related measures and future coronary events. Circulation 2014, 129:553-561.
19. Contois J.H., McConnell J.P., Sethi A.A., Csako G., Devaraj S., Hoefner D.M., et al. Apolipoprotein B and cardiovascular disease risk: position statement from the AACC lipoproteins and vascular diseases division working group on best practices. Clin Chem 2009, 55:407-419.
20. Davidson M.H., Ballantyne C.M., Jacobson T.A., Bittner V.A., Braun L.T., Brown A.S., et al. Clinical utility of inflammatory markers and advanced lipoprotein testing: advice from an expert panel of lipid specialists. J Clin Lipidol 2011, 5:338-367.
21. Tamez-Perez H.E., Proskauer-Pena S.L., Hernrndez-Coria M.I., Garber A.J. AACE comprehensive diabetes management algorithm 2013 endocrine practice. Endocr Pract 2013, 19:736-737.
22. Jeyarajah E.J., Cromwell W.C., Otvos J.D. Lipoprotein particle analysis by nuclear magnetic resonance spectroscopy. Clin Lab Med 2006, 26:847-870.
23. Lounila J., Ala-Korpela M., Jokisaari J., Savolainen M.J., Kesaniemi Y.A. Effects of orientational order and particle size on the NMR line positions of lipoproteins. Phys Rev Lett 1994, 72:4049-4052.
24. Otvos J.D., Jeyarajah E.J., Bennett D.W., Krauss R.M. Development of a proton nuclear magnetic resonance spectroscopic method for determining plasma lipoprotein concentrations and subspecies distributions from a single, rapid measurement. Clin Chem 1992, 38:1632-1638.
25. Smallcombe S.H.P.S., Keifer P.A. Wet solvent suppression and its applications to LC NMR and high-resolution NMR spectroscopy. J Magn Reson 1995, A117:295-303.
26. CLSI document EP17-A: protocols for determination of limits of detection and limits of quantitation; approved guideline 2004, Clinical and Laboratory Standards Institute, Wayne, PA USA.
27. CLSI document EP5-A2: evaluation of precision performance of quantitative measurements methods; approved guideline 2004, Clinical and Laboratory Standards Institute, Wayne, PA. 2nd ed.
28. CLSI document EP6-A: evaluation of the linearity of quantitative measurement procedures: a statistical approach 2003, Clinical and Laboratory Standards Institute, Wayne, PA.
29. Otvos J.D., Jeyarajah E.J., Hayes L.W., Freedman D.S., Janjan N.A., Anderson T. Relationships between the proton nuclear magnetic resonance properties of plasma lipoproteins and cancer. Clin Chem 1991, 37:369-376.
30. CLSI document EP9-A2: method comparison and bias estimation using patient samples; approved guideline 2002, Clinical and Laboratory Standards Institute, Wayne, PA. 2nd ed.
31. CLSI document C28-A3: defining, establishing, and verifying reference intervals in the clinical laboratory; approved guideline 2008, Clinical and Laboratory Standards Institute, Wayne, PA. 3rd ed.
32. CLSI document EP7-A2: interference testing in clinical chemistry; approved guideline 2007, Clinical and Laboratory Standards Institute, Wayne, PA. 2nd ed.
33. Expert panel on detection, evaluation, treatment of high blood cholesterol in adults. Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001, 285:2486-2497.
34. Kathiresan S., Otvos J.D., Sullivan L.M., Keyes M.J., Schaefer E.J., Wilson P.W., et al. Increased small low-density lipoprotein particle number: a prominent feature of the metabolic syndrome in the Framingham Heart Study. Circulation 2006, 113:20-29.
35. Sniderman A.D. Differential response of cholesterol and particle measures of atherogenic lipoproteins to LDL-lowering therapy: Implications for clinical practice. J Clin Lipidol 2008, 2:36-42.
36. Otvos J.D., Jeyarajah E.J., Bennett D.W. Quantification of plasma lipoproteins by proton nuclear magnetic resonance spectroscopy. Clin Chem 1991, 37:377-386.
37. Ala-Korpela M., Kangas A.J., Soininen P. Quantitative high-throughput metabolomics: a new era in epidemiology and genetics. Genome Med 2012, 4:36.
38. Mahendran Y., Vangipurapu J., Cederberg H., Stancakova A., Pihlajamaki J., Soininen P., et al. Association of ketone body levels with hyperglycemia and type 2 diabetes in 9,398 Finnish men. Diabetes 2013, 62(10):3618-3626.
39. Tukiainen T., Tynkkynen T., Makinen V.P., Jylanki P., Kangas A., Hokkanen J., et al. A multi-metabolite analysis of serum by 1H NMR spectroscopy: early systemic signs of Alzheimer's disease. Biochem Biophys Res Commun 2008, 375:356-361.
40. von Beckerath N., Taubert D., Pogatsa-Murray G., Schomig E., Kastrati A., Schomig A. Absorption, metabolization, and antiplatelet effects of 300-, 600-, and 900-mg loading doses of clopidogrel: results of the ISAR-CHOICE (intracoronary stenting and antithrombotic regimen: choose between 3 high oral doses for immediate clopidogrel effect) trial. Circulation 2005, 112:2946-2950.